We previously demonstrated that therapy duration has a differential impact on susceptible and resistant subpopulations of Staphylococcus aureus. What our previous investigation did not address was what would transpire after stopping therapy and whether these events would be different in susceptible and resistant subpopulations. We used the regimen previously demonstrated to amplify resistant subpopulation at day 4 -5 (area under the concentration-time curve/minimum inhibitory concentration ratio, 100). Therapy was started in our hollow-fiber infection model on day 0; garenoxacin was administered in 4, 5, or 6 doses (days 3-5). The system was observed until day 13. Four drug doses kept the susceptible population dominant, but with the resistant subpopulation amplifying. Five and 6 doses caused the resistant population to exceed the susceptible population at the end of therapy and for a variable time thereafter. Ultimately, the susceptible population became dominant by day 13. Modeling demonstrated that the resistant isolates grew more slowly and had a higher natural death rate.
We previously demonstrated that therapy duration has a differential impact on susceptible and resistant subpopulations of Staphylococcus aureus. What our previous investigation did not address was what would transpire after stopping therapy and whether these events would be different in susceptible and resistant subpopulations. We used the regimen previously demonstrated to amplify resistant subpopulation at day 4 -5 (area under the concentration-time curve/minimum inhibitory concentration ratio, 100). Therapy was started in our hollow-fiber infection model on day 0; garenoxacin was administered in 4, 5, or 6 doses (days 3-5). The system was observed until day 13. Four drug doses kept the susceptible population dominant, but with the resistant subpopulation amplifying. Five and 6 doses caused the resistant population to exceed the susceptible population at the end of therapy and for a variable time thereafter. Ultimately, the susceptible population became dominant by day 13. Modeling demonstrated that the resistant isolates grew more slowly and had a higher natural death rate.
We have recently examined the differential impact of the duration of quinolone therapy on susceptible and resistant organism populations [1] . This paper represents an extension of those findings. We were able to demonstrate that one could obtain a maximal killing rate with 2 different regimens (area under the concentration-time curve/minimum inhibitory concentration [AUC/MIC] ratios of 100 and 280), yet still differentiate the regimens on the basis of their impact on the 2 different populations of susceptible and resistant organisms. For 4 -5 days, both regimens gave maximal kill responses. After day 5, the regimen of AUC/MIC ratio 100 allowed amplification of the resistant population, whereas the regimen of AUC/MIC ratio 280 suppressed the resistant population for the whole 10 days of therapy. Given this result, we called for adequate, but short-course, regimens.
One of us indicated in a conversation that we had not examined the ultimate impact on the susceptible and resistant populations after therapy was stopped. Most importantly, the question was posed, "Did regimens that did not suppress resistant mutant amplification allow these to be dominant after therapy was discontinued?" Given that short-course regimens are becoming quite popular [2] , we felt it was critical to delineate the answer to this question. Consequently, we employed our hollow-fiber infection model and examined a notreatment control and 3 other regimens-each producing a daily AUC/MIC ratio of 100 -in which 4, 5, or 6 doses of the quinolone garenoxacin were administered and followed with no further treatment until day 13.
METHODS

Microorganism.
A methicillin-susceptible Staphylococcus aureus strain ([MSSA] ATCC 25925) was used. S. aureus (ATCC 25925) was stored in skim milk at Ϫ70°C. The isolate was subcultured on blood agar plates twice before each experiment. Susceptibility to garenoxacin was determined in duplicate testing by use of the mac-robroth dilution method described by the National Committee for Clinical Laboratory Standards in cation-adjusted MuellerHinton II broth [3] . Susceptibility testing was repeated with 10% cation-adjusted Mueller-Hinton II broth plus 90% clarified pooled human serum. Minimal bactericidal concentration (MBC) was determined by subculturing 100 L from the tube onto cation-adjusted Mueller-Hinton II plates and determining the concentration that reduced the inoculum by 99.9%.
Susceptibility test methods for resistant mutants. Strains were tested against the quinolone agent garenoxacin (kindly supplied by Schering-Plough) by use of the broth microdilution method described by the Clinical and Laboratory Standards Institute (CLSI) [4] in cation-adjusted Mueller-Hinton II broth.
Determination of garenoxacin protein binding. Garenoxacin was dissolved in pooled human serum in concentrations ranging from 0.2 mg/L to 20 mg/L. Protein binding was determined by an ultracentrifugation technique [5] , by use of the high-performance liquid chromatography (HPLC) assay mentioned below.
Hollow-fiber infection model. A schematic diagram of the system is as shown in figure 1 . Garenoxacin was directly injected into the central reservoir over a period of 1 h once daily for 4, 5, or 6 doses days to achieve the peak concentration desired at 1 h into the dosing interval. The methods specific to the operation of this model have been published previously [1] .
Duration-response studies. S. aureus (ATCC 25925) was stored, subcultured, and tested for susceptibility to garenoxacin as described above. The bacterial inoculum was prepared by employing 3 medium-sized colonies grown overnight in MuellerHinton II broth at 35°C. The hollow-fiber systems were maintained at 35°C in a humidified incubator. Fifteen milliliters of bacterial culture broth containing bacteria in late log phase growth (2.38 ϫ 10 7 cfu/mL) were infused into 4 hollow fiber cartridges, 1 for a nominal drug exposure (AUC 24 /MIC) of 0 (control) and 3 for the 3 drug regimens designed to achieve AUC/MIC values of 100 administered as 4, 5, or 6 doses. These regimens simulated the steady-state human pharmacokinetics of unbound garenoxacin, given once every 24 h (t1/ 2 ϭ 12.8 h; clearance, 6 L/h) [6] . Experimentally attained garenoxacin exposures (central compartment) were based on drug concentrations quantified by a validated HPLC method [2] at 1, 3, 5, 9, 11, 23, 25, 27, 29, 33, 35, and 47 h. On day 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 13, samples of the bacterial cultures were obtained, centrifuged at 3200 g for 15 min, resuspended in normal saline to minimize drug carryover effect, and serially diluted 10-fold. The serially diluted samples were quantitatively cultured on drug-free Mueller-Hinton II agar plates to enumerate the total bacterial population. The garenoxacin-resistant bacterial subpopulation was quantified by culture on media plates supplemented with garenoxacin at a concentration 3 times the baseline MIC. The media plates were incubated at 35°C for 24 and 72 h to evaluate the impact on the total population and the antibiotic-resistant subpopulation, respectively. At the end of the experiment, the garenoxacin MIC values for the resistant subpopulations were determined to confirm resistance.
Modeling methods. To mathematically determine the minimal drug exposure necessary to suppress the emergence of resistance, 3 simultaneous, parallel, inhomogeneous differential equations (shown below) were used to describe the changes over time in the garenoxacin concentrations and the total and resistant subpopulations. Multiple drug regimens as well as a control regimen were simultaneously comodeled in a population sense by use of the population modeling program Big NPAG [7] . Bayesian estimates were generated for each regimen. The parameter estimates from the Bayesian best-fit model were then incorporated into the subroutines of ADAPT II [8] , and the biological responses of the susceptible and resistant bacterial subpopulations as the duration of drug exposure escalated were calculated. The mass-balance equations that describe the subpopulations of interest (garenoxacin-susceptible and resistant microorganisms) are
(1)
These equations differ from those published previously [1] by virtue of the addition of a natural kill rate constant (K nat ) for both susceptible and resistant subpopulations. This is made possible by observation of the organisms for different time periods off therapy, after drug had been cleared from the system. Equation (1) describes drug pharmacokinetics in the hollowfiber system (a standard 1-compartment open model with 0-order input and first-order elimination). X 1 is the amount of drug in the central compartment; R(1) is the 0-order, timedelimited drug-infusion rate into the central compartment (in milligrams per hour); SCL is the rate of clearance of drug from the central compartment (in liters per hour); and V c is the volume of the central compartment. Equations (2) and (3) describe the rates of change of the garenoxacin-susceptible and -resistant subpopulations, respectively, over time. The model equations for describing the rate of change of the numbers of microorganisms in the susceptible and resistant bacterial subpopulations were developed on the basis of the in vitro observation that bacteria in the hollow-fiber system are in logarithmic growth phase in the absence of the drug and exhibit an exponential densitylimited growth rate:
There is 1 equation to describe the susceptible bacterial subpopulation (equation [2] ) and 1 for the resistant subpopulation (equation [3] ). In each, first-order growth was assumed up to a density limit. Each subpopulation has an independent growth rate constant (for the susceptible subpopulation, K gmax-S ; for the resistant subpopulation, K gmax-R ). As the microorganisms approach maximal bacterial density, they approach stationary phase. This is accomplished by multiplying the first-order growth terms by E (a logistic growth term; equation [4] ). The maximal bacterial density (POP max ) is identified as part of the estimation process. Most of the information for identifying this parameter is derived from the bacterial growth in the control group. Equations (2) and (3) also allow modeling of the antibacterial effect of the drug doses administered. For both susceptible and resistant subpopulations, there is an independent effect of the drug dose on the 2 populations, 1 mediated through equation (2) (the susceptible subpopulation) and 1 through equation (3) is the drug concentration (in milligrams per liter) needed to achieve 50% of the maximal kill rate. As noted above, a natural death rate constant is included for both subpopulations (K nat-S and K nat-R ):
Separate H and EC 50 terms are provided for the susceptible and resistant subpopulations. The drug effect observed is a balance between growth and death induced by the drug concentrations achieved and the natural death terms. N S and N R are the number of colony-forming units per milliliter for the susceptible and resistant subpopulations, respectively. The measured outputs were changes in garenoxacin concentration over time and changes in total population (N S ϩ N R ) and resistant mutant (N R ) population densities; the susceptible and resistant subpopulations were enumerated on drug-free plates and plates containing 3 times the baseline MIC of the drug, respectively. Impact of escalating duration of garenoxacin exposure on the total and resistant bacterial populations. The changes over time in colony-forming units per milliliter for both the total population and the resistant subpopulation (i.e., organisms resistant to 3 times the baseline MIC) over the 13 days of the experiment are displayed in figure 2A-2D . The number of mutants as a percentage of the total population can be seen to decline slightly in figure 2A . The actual AUC/MIC ratio achieved, as calculated from the parameter values, was 105 (the nominal value desired was 100). Figure 2B shows that, as we had seen in our previous work [1] , an AUC/MIC ratio of approximately 100 resulted in an excellent kill rate for the total population, but even after 4 doses, one can see the beginning of the resistance amplification by day 4, which is 24 h after the last administered dose. From day 5 through 9, we see the total population expand to its maximal level. One can also see the resistant population expand, but at a slower rate and, importantly, after day 7, the number of resistant organisms declines. In figure 2C and 2D, we see exactly the same general trends, except that for shorter (2C) or longer (2D) periods, the total population size is approximated by the resistant subpopulation size, and the slower regrowth rates of the resistant subpopulation is somewhat easier to see.
RESULTS
MIC
It should also be noted that the system reproducibility is excellent. As each treated hollow-fiber unit is an independent event, one can gauge reproducibility by examining the part of the experiment that is common to all 3 treated systems: the time up to 24 h after the fourth dose. The results are highly concordant, as demonstrated in figure 3 .
Fit of the model to the data. The fit of the model to the data was quite acceptable for all 3 measured system outputs. The parameter values for the population model are displayed in table 1.
For output 1, the measured garenoxacin concentrations, the equation for the predicted-observed plot after the Bayesian step was: observed concentration ϭ 0.966 ϫ observed concentration ϩ 0.0114; r 2 ϭ 0.953, P Ͻ Ͻ .001; mean weighted error (bias) ϭ Ϫ0.0258 mg/L; bias-adjusted mean weighted squared error (precision) ϭ 0.899 (mg/L) 2 .
For output 2, the total S. aureus colony counts, the equation for the predicted-observed plot after the Bayesian step was: observed counts ϭ 0.993 ϫ predicted counts ϩ 0.0472; r 2 ϭ 0.975, P Ͻ Ͻ .001; mean weighted error (bias) ϭ 0.010 mg/L; biasadjusted mean weighted squared error (precision) ϭ 0.961 (mg/L) 2 .
For output 3, the resistant S. aureus colony counts, the equation for the predicted-observed plot after the Bayesian step was: observed resistant counts ϭ 1.001 ϫ predicted resistant counts ϩ 0.0126; r 2 ϭ 0.893, P Ͻ Ͻ .001; mean weighted error (bias) ϭ 0.0026 mg/L; bias-adjusted mean weighted squared error (precision) ϭ 0.688 (mg/L) 2 .
95% Confidence intervals for the growth and natural death rate constants for the susceptible and resistant bacterial subpopulations. In table 2, we display median Bayesian parameter estimates and 95% confidence intervals for the growth rate and natural death rate constants for the susceptible and resistant subpopulations in different hollow-fiber units that received 4, 5, or 6 doses of garenoxacin. In each instance, the growth rate constant for the susceptible population is larger than that for the resistant population and the 95% confidence intervals do not overlap, indicating statistically significant difference between the Initial total population, cfu/mL 3.00 ϫ 10 7 (5.50 ϫ 10 6 )
Initial resistant population, cfu/mL 146 (80) NOTE. C 50k , H k , K nat , Kg max , and Kk max , are shown for susceptible (S) and resistant (R) subpopulations. C 50k , drug concentration needed to achieve 50% of the maximal kill rate; H k , sigmoidicity constant for microbial kill; K nat , natural death rate constant; Kg max , rate constant for maximum bacterial growth; Kk max , rate constant for maximal bacterial kill; POP max , estimated maximal size of the bacterial density of control hollowfiber system bacteria after bacterial growth enters stationary phase. rate constants for the susceptible and resistant population. Likewise, for the natural death rate constant, the resistant subpopulation has the highest values and the confidence intervals do not overlap. Again, this indicates significant difference.
DISCUSSION
We had previously demonstrated that the duration of therapy had an impact on the ability to suppress the amplification of a resistant population [1] . The longer therapy continues, the more intense the drug exposure needs to be to maintain suppression of this population. Consequently, we concluded from this finding that shorter durations of therapy may help control resistance, even for less-than-optimal regimens.
One of the authors indicated that we had not actually observed the behavior of the total and resistant populations after cessation of a short course of quinolone therapy and that, therefore, the suggestion of short courses may have been misguided. We recognized the correctness of this observation and wanted to generate data on the basis of 4, 5, and 6 doses of the quinolone garenoxacin used against the same strain of S. aureus we had used previously and carry out the observations for Ͼ1 week after the last dose to examine any differential impact of drug exposure on the susceptible and resistant populations.
The outcome was quite clear. In all instances, the rate of initial cell kill was much like that we had observed earlier, and the response of the resistant population was also concordant with our earlier work [1] . When therapy halted, the total population continued to decline for approximately 36 h, attributable to the slowly declining drug concentrations.
To clearly sort out the behavior of the different subpopulations, we calculated the behavior of the susceptible population by subtracting the modeled resistant subpopulation from the modeled total population (figure4A-4D). The no-treatment control (4A) shows the expected total population behavior, rapidly rising to a maximal value Ͼ10 log 10 cfu/mL. Because the resistant population is relatively small, the susceptible population and the total population are virtually concordant. It should be noted, however, that the modeled resistant population declines slightly with time.
With 4 doses of drug, we saw that cell kill (total population) ceases just prior to day 5, but that the resistant population starts regrowth at ϳ4.35 days. Importantly, the susceptible population never approaches the size of the resistant population, and the total and susceptible populations appear concordant. One sees that the regrowth of the susceptible population is more rapid than that of the resistant population. Finally, it is clear that after 7.6 days, the number of resistant isolates declines, while the susceptible population (and hence the total population) increases slightly.
The same pattern is repeated with 5 doses (figure 4C) and 6 doses ( figure 4D ), except that here, the susceptible subpopulation declines below the level of the resistant subpopulation and, at least for a while, the resistant population appears to make up the total population. However, as there are still a few susceptible organisms remaining, when susceptible subpopulation regrowth initiates, they quickly outstrip the growth of the resistant subpopulation and after day 6 (for the organisms that received 5 doses) or 7 (for the organisms that received 6 doses), the susceptible population dominates. Also in both, the resistant population declines after day 9.75 (for the organisms that received 5 doses) or day 10 (for the organisms that received 6 doses).
There are 2 important take-home messages. The first is that even nonoptimal regimens can be of use. As long as we obtain sufficient kill, such that white-cell defenses can be brought to bear for eradication of the bacterial burden, we can use such a regimen without engendering a bad outcome. However, the regimen needs to be short enough not to wipe out the susceptible population and allow the resistant population to increase enough so that white-cell defenses can no longer do the job of controlling the infection. Clinically, this would be perceived as the emergence of resistance with clinical failure, which is less common than the emergence of resistance without clinical failure. The next question to be addressed by this laboratory will be the level to which the organism population needs to decline for white cells to be sufficient to clear the infection.
The second is that the behavior of the resistant subpopulation needs to be understood. The growth rate of the susceptible population is always greater (significantly so) than that of the resistant population. This can be interpreted as the resistant organism being less biologically fit. This was also seen in the no- treatment control, where the growth constants for susceptible and resistant populations were 8.04 and 2.16 log 10 (cfu/mL)/h, respectively, with nonoverlapping 95% confidence intervals. Interestingly, we were able to estimate a natural death rate as part of this model because of a long period of time with very low drug concentrations was available for observation. This natural death rate constant was always higher for the resistant population than for the susceptible population, for all the treated units. Of interest, this was not the case for the untreated control, where the natural death rate constant was almost 3 times greater for the susceptible population, compared with the resistant population (1.516 vs. 0.6057 log 10 [cfu/mL]/h, respectively), with nonoverlapping confidence intervals. We intend to use this observation as a hypothesis generator regarding the effect of past quinolone exposure on the surviving parts of the population.
In summary, short-course therapy will not lead to problems with amplifying mutant subpopulations, even if a less-thanoptimal regimen is employed (as was the case here), unless it goes on long enough to eradicate the susceptible subpopulation while amplifying the resistant subpopulation. To confidently generate optimal short-course therapy for infections, it will be important to ascertain how low the total bacterial burden needs to be driven by chemotherapy so that the immune system can eradicate the remaining bacteria.
